Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 391

1.

Sodium-Glucose Co-transporter-2 Inhibitors and Diabetic Ketoacidosis. An Updated Review of the Literature.

Bonora BM, Avogaro A, Fadini GP.

Diabetes Obes Metab. 2017 May 18. doi: 10.1111/dom.13012. [Epub ahead of print] Review.

PMID:
28517913
2.

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.

Fadini GP, Bonora BM, Avogaro A.

Diabetologia. 2017 May 12. doi: 10.1007/s00125-017-4301-8. [Epub ahead of print]

PMID:
28500396
3.

Intraclass differences in the risk of hospitalisazion for heart failure among type 2 diabetic patients initiating a dipeptydil peptidase-4 inhibitor or a sulphonylurea. Results from the OsMed Health-DB registry.

Fadini GP, Saragoni S, Russo P, Degli Esposti L, Vigili de Kreutzenberg S, Melazzini M, Avogaro A; OsMed Health DB Network‡..

Diabetes Obes Metab. 2017 Apr 21. doi: 10.1111/dom.12979. [Epub ahead of print]

PMID:
28432754
4.

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.

Avogaro A, Giaccari A, Fioretto P, Genovese S, Purrello F, Giorgino F, Del Prato S.

Expert Rev Clin Pharmacol. 2017 May 2:1-10. doi: 10.1080/17512433.2017.1322507. [Epub ahead of print]

PMID:
28431476
5.

Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study.

Vigili de Kreutzenberg S, Solini A, Vitolo E, Boi A, Bacci S, Cocozza S, Nappo R, Rivellese A, Avogaro A, Baroni MG.

J Diabetes Complications. 2017 Jun;31(6):952-957. doi: 10.1016/j.jdiacomp.2017.03.014. Epub 2017 Apr 4.

PMID:
28416121
6.

Mechanisms linking empagliflozin to cardiovascular and renal protection.

Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E.

Int J Cardiol. 2017 Mar 23. pii: S0167-5273(17)31358-X. doi: 10.1016/j.ijcard.2017.03.089. [Epub ahead of print]

PMID:
28395981
7.

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.

Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, Albiero M, Avogaro A.

Cardiovasc Diabetol. 2017 Apr 4;16(1):42. doi: 10.1186/s12933-017-0529-3.

8.

Persistent reduction of circulating myeloid calcifying cells in acromegaly. Relevance to the bone-vascular axis.

Fadini GP, Dassie F, Cappellari R, Persano M, Vigili de Kreutzenberg S, Martini C, Parolin M, Avogaro A, Vettor R, Maffei P.

J Clin Endocrinol Metab. 2017 Mar 17. doi: 10.1210/jc.2017-00246. [Epub ahead of print]

PMID:
28323966
9.

Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance.

Fadini GP, Tura A, Pacini G, Avogaro A, Vigili de Kreutzenberg S.

Atherosclerosis. 2017 Jun;261:117-123. doi: 10.1016/j.atherosclerosis.2017.03.002. Epub 2017 Mar 6.

PMID:
28298252
10.

Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.

Fioretto P, Avogaro A.

Expert Opin Pharmacother. 2017 Apr;18(5):517-527. doi: 10.1080/14656566.2017.1300253. Epub 2017 Mar 20. Review.

PMID:
28277831
11.

The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography.

Vigili de Kreutzenberg S, Avogaro A.

J Endocrinol Invest. 2017 Feb 11. doi: 10.1007/s40618-017-0615-0. [Epub ahead of print]

PMID:
28188583
12.

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.

Fadini GP, Bonora BM, Albiero M, Zaninotto M, Plebani M, Avogaro A.

Cardiovasc Diabetol. 2017 Feb 10;16(1):22. doi: 10.1186/s12933-017-0507-9.

13.

[Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].

Avogaro A.

G Ital Cardiol (Rome). 2016 Dec;17(12 Suppl 2):3S-12. doi: 10.1714/2616.26910. Italian.

PMID:
28151516
14.

Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy.

Indelicato L, Mariano V, Galasso S, Boscari F, Cipponeri E, Negri C, Frigo A, Avogaro A, Bonora E, Trombetta M, Bruttomesso D.

Diabet Med. 2017 May;34(5):691-697. doi: 10.1111/dme.13321. Epub 2017 Feb 20.

PMID:
28145047
15.

Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study.

Vitale M, Masulli M, Rivellese AA, Bonora E, Cappellini F, Nicolucci A, Squatrito S, Antenucci D, Barrea A, Bianchi C, Bianchini F, Fontana L, Fornengo P, Giorgino F, Gnasso A, Mannucci E, Mazzotti A, Nappo R, Palena AP, Pata P, Perriello G, Potenziani S, Radin R, Ricci L, Romeo F, Santini C, Scarponi M, Serra R, Timi A, Turco AA, Vedovato M, Zavaroni D, Grioni S, Riccardi G, Vaccaro O; TOSCA.IT Study Group..

Eur J Nutr. 2016 Dec 21. doi: 10.1007/s00394-016-1355-1. [Epub ahead of print]

PMID:
28004268
16.

Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.

Kovatchev B, Cheng P, Anderson SM, Pinsker JE, Boscari F, Buckingham BA, Doyle FJ 3rd, Hood KK, Brown SA, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Ly TT, Shanmugham S, Dassau E, Kollman C, Lum JW, Beck RW.

Diabetes Technol Ther. 2017 Jan;19(1):18-24. doi: 10.1089/dia.2016.0333. Epub 2016 Dec 16.

PMID:
27982707
17.

Erratum to: Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures.

Scattolini V, Luni C, Zambon A, Galvanin S, Gagliano O, Ciubotaru CD, Avogaro A, Mammano F, Elvassore N, Fadini GP.

Diabetes Ther. 2017 Feb;8(1):207. doi: 10.1007/s13300-016-0216-5. No abstract available.

18.

Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures.

Scattolini V, Luni C, Zambon A, Galvanin S, Gagliano O, Ciubotaru CD, Avogaro A, Mammano F, Elvassore N, Fadini GP.

Diabetes Ther. 2016 Dec;7(4):679-693. Epub 2016 Nov 9. Erratum in: Diabetes Ther. 2016 Nov 30;:. Diabetes Ther. 2017 Feb;8(1):207.

19.

Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes.

Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A.

Diabetes Care. 2017 Jan;40(1):125-131. doi: 10.2337/dc16-1755. Epub 2016 Nov 4.

PMID:
27815289
20.

Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial.

Kropff J, DeJong J, Del Favero S, Place J, Messori M, Coestier B, Farret A, Boscari F, Galasso S, Avogaro A, Bruttomesso D, Cobelli C, Renard E, Magni L, DeVries JH; AP@home consortium..

Diabet Med. 2017 Feb;34(2):262-271. doi: 10.1111/dme.13268. Epub 2016 Oct 28.

Supplemental Content

Loading ...
Support Center